Form 4: Armata Pharmaceuticals Director Acquires Stock Options

Director Odysseas Kostas D. of Armata Pharmaceuticals acquired stock options on February 5, 2025.

Summary

• On February 5, 2025, Odysseas Kostas D., a director of Armata Pharmaceuticals, Inc., acquired 54,343 stock options.
• The options have an exercise price of $2.04.
• The options vest in two tranches: 50% on February 5, 2026, and the remaining 50% on February 5, 2027, contingent upon continuous service.
• The expiration date for these options is February 5, 2035.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a standard disclosure of stock option grants, which is neither particularly positive nor negative on its own. The positive aspect is that the director is incentivized to improve the company's performance.

Positives

• The acquisition of stock options by a director can be seen as a positive sign, indicating confidence in the company's future performance.

Industry Context

This filing is a routine disclosure related to insider transactions, which are common in the pharmaceutical industry as part of executive compensation packages.

Comparison to Industry Standards

• Stock option grants are a standard component of executive compensation in the pharmaceutical industry, used to align management's interests with those of shareholders.
• The vesting schedule of 50% per year over two years is a typical vesting arrangement.
• The exercise price of $2.04 would need to be compared to the market price of ARMP stock at the time of the grant to assess its value.

Stakeholder Impact

• The stock option grant aligns the director's interests with those of shareholders, potentially encouraging actions that increase shareholder value.

Key Dates

Keywords

stock options, director, acquisition, Armata Pharmaceuticals, ARMP, Odysseas Kostas, beneficial ownership, Form 4